Replies to post #439444 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Both SNO and ESMO confirmed their intent to use the new definition BEFORE WHO formalized it.

Also, the new definition excluded secondary GBM, but added these:

According to cIMPACT-NOW 3, IDH-wild-type astrocytomas, WHO grades 2 and 3, can be considered to behave as de facto glioblastomas, when the following molecular criteria are fulfilled: EGFR amplification and/or whole chromosome 7 gain and whole chromosome 10 loss (+7/-10) and/or TERT promoter mutation. In other words, reliable molecular readouts have made it possible to predict outcome in biopsies that do not fulfill the histological criteria of glioblastoma